Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target

por Fernandez, Marta Llaurado, Dawson, Amy, Hoenisch, Joshua, Kim, Hannah, Bamford, Sylvia, Salamanca, Clara, DiMattia, Gabriel, Shepherd, Trevor, Cremona, Mattia, Hennessy, Bryan, Anderson, Shawn, Volik, Stanislav, Collins, Colin C., Huntsman, David G., Carey, Mark S.
Publicado 2019

Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression

por Cheasley, Dane, Fernandez, Marta Llaurado, Köbel, Martin, Kim, Hannah, Dawson, Amy, Hoenisch, Joshua, Bittner, Madison, Chiu, Derek S., Talhouk, Aline, Gilks, C. Blake, Jayawardana, Madawa W., Pishas, Kathleen I., Mes-Masson, Anne-Marie, Provencher, Diane, Nigam, Abhimanyu, Hacker, Neville F., Gorringe, Kylie L., Campbell, Ian G., Carey, Mark S.
Publicado 2022

NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition

por Llaurado Fernandez, Marta, Hijmans, E. Marielle, Gennissen, Annemiek M.C., Wong, Nelson K.Y., Li, Shang, Wisman, G. Bea A., Hamilton, Aleksandra, Hoenisch, Joshua, Dawson, Amy, Lee, Cheng-Han, Bittner, Madison, Kim, Hannah, DiMattia, Gabriel E., Lok, Christianne A.R., Lieftink, Cor, Beijersbergen, Roderick L., de Jong, Steven, Carey, Mark S., Bernards, René, Berns, Katrien
Publicado 2022